Views & Analysis PRIME movers: taking stock of the EMA's scheme Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
News UK follows through on doubling of statutory scheme rate UK pharma firms have reacted angrily to the news that the government has doubled the statutory scheme rebate on the sales of newer drugs to the NHS.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
